What is it about?
In clinical trials and research generally, there has been an increasing shift towards remote clinical assessment and decentralized trials, to support patient centricity goals around improved access, and to increase trial efficiency. The Cogstate Brief Battery is one such remote assessment solution, which was initially included in ADNI-2 as a pilot evaluation and is currently part of the ongoing ADNI-3 study. The present data provide important insights into the feasibility and validity of the CBB as an at-home, ‘bring your own device’ (BYOD) assessment of cognition, and also present a broader evaluative framework for the practical application of such assessments in clinical trials.
Photo by CDC on Unsplash
Why is it important?
The ongoing COVID-19 pandemic has created a necessity for remote assessment to support continued trial conduct in the context of social distancing against this existing background trend. This inflection point has created increased demand for remote assessment but has also exposed challenges with the adaptation of traditional clinical trial outcome assessments for Alzheimer’s disease. Thus, development and validation of remote assessments is critical to the future of clinical trials and is of great interest to the field.
Read the Original
This page is a summary of: Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2, Journal of Alzheimer s Disease, September 2021, IOS Press, DOI: 10.3233/jad-210201.
You can read the full text:
The following have contributed to this page